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regression analyses were conducted to compare the time to ﬁ rst antipsychotic drug 
dispensing between the rivastigmine and donepezil groups. RESULTS: A total of 532 
patients receiving rivastigmine and 7,264 patients receiving donepezil were studied.
The donepezil group was slightly older (81.1 vs. 79.9 years; p  0.0044) with a greater 
proportion of women (59.4% vs. 53.2%; p  0.0053). The Kaplan-Meier analysis 
showed that 30 (5.6%) rivastigmine and 589 (8.1%) donepezil patients received anti-
psychotic medications (Log-rank p  0.0672). Multivariate adjustment showed that 
rivastigmine was associated with a statistically signiﬁ cant reduction in emergent use 
of antipsychotic drugs by 34% relative to donepezil (hazard ratio: 0.66; 95% CI:
0.46–0.96; p  0.0305). Among other statistically signiﬁ cant covariates, older age, 
lower drug dose, baseline depression and neuropsychiatric symptoms, and admission 
to inpatient long-term care facilities were associated with an increased likelihood of 
antipsychotic drug use. CONCLUSIONS: Based on real-world data from a large
cohort of antipsychotic-naïve patients with AD, rivastigmine was found to be associ-
ated with a signiﬁ cant reduction in the emergent use of antipsychotic drugs, compared
to donepezil. Prospective studies are needed to verify these ﬁ ndings.
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OBJECTIVES: We have initiated a project to identify statistically independent dimen-
sions of health services utilization in epilepsy. A desirable covariate for this analysis 
is the type of convulsive disorder. Here we report on the classiﬁ cation of epilepsy 
patients using insurance data. METHODS: We applied an iterative classiﬁ cation
technique to patients’ sequences of insurance claims for outpatient and inpatient ser-
vices, diagnostic procedures and drugs. The target population included 122,850 US
commercial insurance and Medicare supplement subscribers with a physician visit
diagnosis of ICD-9 345xx. We classiﬁ ed persons into the ICD-9 coding scheme (or as 
“not epilepsy”) by developing a family of rules corresponding to empirically observed 
claims patterns. We sampled patient histories in blocks of 50. Within each claims
history, a neuroepidemiologist looked for diagnosis, procedure and treatment patterns
that pointed to a clinical diagnosis, and added that pattern to the rule deﬁ ning a
diagnostic type. Removing classiﬁ ed patients, we sampled remaining claims histories
and repeated the process of classiﬁ cation and removal and sampling until 50 claims 
histories suggested no new classiﬁ cation rules. Remaining patients were tagged as
unclassiﬁ able. Finally, we reviewed samples of the classiﬁ ed patients to identify dis-
qualiﬁ cation criteria. RESULTS: The majority of patients are classiﬁ able and the
empirical classiﬁ cation rules “make sense” clinically (e.g. diagnostic changes are per-
mitted immediately if they follow a diagnostic procedure). A signiﬁ cant minority of 
cases of epilepsy have only nonspeciﬁ c treatment codes assigned. CONCLUSIONS:
There are clear examples of patients with different clinical subtypes of epilepsy in
claims data, and it will be possible to derive average utilization characteristics and
drivers for different types of epilepsy. Analysis of the dimensions of health care utiliza-
tion (combinations of drugs, procedures, physician and hospital) may yield further
insight into currently unclassiﬁ able cases and will provide sensitive measures of the
cost impact of new therapies.
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OBJECTIVES: Generic substitution might produce economic impacts beyond the
reduction in spending for new generic product, such as increased number of users,
and utilization of health care resources. The current study forecasts the economic
impact of generic entry of the antiepileptic drug (AED) topiramate into the settings of 
France, Germany, Italy, and the UK. METHODS: Health claims from Québec’s pro-
vincial health plan (RAMQ) from January 2006 to September 2008, and IMS Health 
data on European AED sales between 1998 and 2008 were used. Patient-level health
care utilization and costs in Canada were calculated during mutually-exclusive periods
of brand versus generic use of topiramate (Topamax). Annualized Canadian health
care costs were projected for periods of branded and generic use in each country 
(€2007/person-year). Using market-level sales, branded and generic topiramate utiliza-
tion were forecasted for 12 months following expected generic entry (September 
2009-September 2010) using autoregressive and panel-data regression models. The 
economic impact of generic entry was projected for each country, stratiﬁ ed into its
effect on market size, topiramate costs, and other health care costs. Budgetary conse-
quences for individual, private, and government payers were assessed. RESULTS:
Projected per-patient health care costs in G4 European countries, excluding topira-
mate, would be signiﬁ cantly higher during generic-use periods (adjusted cost differ-
ences per person-year: €706 to €815, p  0.001 for all comparisons) compared to
brand-use periods. Assuming mandatory generic substitution for all patients, predicted 
system-wide increases in total adjusted health care costs would range from 3.5% (UK)
to 24.4% (France) 1 year after generic entry. Increases in non-topiramate health care
costs (13.7% to 18.1%) would more than offset savings in topiramate costs (–6.3% 
to 13.8%) in France, Italy, and the UK. These impacts would be evenly distributed 
among payers of each country. CONCLUSIONS: Generic entry of topiramate in
Europe would represent a trade-off between reduced generic drug expenditures and 
increased health care costs.
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OBJECTIVES: To determine if dispending channel (specialty pharmacy versus retail) 
impacts medication adherence for patients receiving therapy for Multiple Sclerosis
(MS). METHODS: Retrospective pharmacy claims for MS patients were extracted for 
2007–2008. Patients were followed for 12 months from the index claim. Adherence 
was measured using a Medication possession ratio (MPR), with patients considered 
adherent if MPR q 80%. Propensity scoring was used in the sample selection. Differ-
ences of demographics were evaluated using the Wilcoxon signed-rank test for con-
tinuous variable and the chi-square test for the categorical variable. Generalize linear
regression was used to calculate the adjusted mean adherence. RESULTS: From a study 
population of 31,593 MS patients, a matched sample of 19,742 was chosen (9,871 in
the specialty and retail channel). There were no differences in demographics between 
the samples, with 76.19% female and mean age of 48.84. Overall comparison showed 
an average MPR of 89.94% for specialty and 84.08% for retail; with 81.52% of 
specialty patients adherent (MPR  80%) vs. 71.18% of retail patients. The results
were similar for each individual MS therapy. The following list the drug, and the 
percent of specialty and retail patients at least 80% adherent: Interferon beta-1a 
(Avonex) 87.49% vs. 78.13%, interferon beta-1a (Rebif) 80.97% vs. 75.50%, inter-
feron beta-1b 79.16% vs. 66.48%, glatiramer acetate 78.26% vs. 63.81%. (Average
MPRs for each drug available on the poster.) All comparisons were statistically sig-
niﬁ cant (P  .05). CONCLUSIONS: Patients who receive their MS medication from 
a specialty pharmacy are much more likely to be adherent than those who receive 
medication from a retail pharmacy. This is true across the broad category, as well as
each individual therapy. Specialty pharmacy offers enhanced patient counseling and 
clinical services, which may explain differences in adherence. Follow up studies will 
explore the impact of improved adherence on clinical and economic outcomes.
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OBJECTIVES: To review postmarketing surveillance data in order to examine reports 
of progressive multifocal leukoencephalopathy (PML) in patients using natalizumab 
for multiple sclerosis (MS) before and after the implementation of a natalizumab Risk 
Minimization Action Plan (RiskMAP) in the United States (US). METHODS: The 
Adverse Event Reporting System (AERS) database was searched for reports of serious 
adverse events of PML associated with natalizumab in MS patients during the pre- 
(November 23, 2004-February 28, 2005) and post-RiskMAP (July 2006-June 2008)
periods. AERS reports listing, 1) Tysabri or natalizumab as primary suspect drug; 2) 
events of PML; and 3) natalizumab-PML combination reports were extracted. Dupli-
cate reports and drug redundancies were excluded; in the event of duplicate case
reports, the report with the most recent date was used. Reports from foreign countries 
were excluded to focus the analysis on US-related events and to exclude variations 
due to different governmental requirements and national post-marketing surveillance 
systems. RESULTS: A total of 576,072 unduplicated reports were identiﬁ ed during 
the post-RiskMAP period in the US. A hands-on review of the reports of PML and
tysabri/natalizumab identiﬁ ed 41 and 1221 unduplicated US reports respectively, 
during the post-RiskMAP period. There were two conﬁ rmed cases (from previous lit-
erature) of PML associated with natalizumab before RiskMAP implementation and 
eight reported cases following RiskMAP implementation. The mean age of reported
natalizumab-PML cases post-RiskMAP was 50.6 years, and 7 of the cases (87.5%)
were in females. CONCLUSIONS: The extracted reports from the AERS indicate
continuing case reports for PML associated with natalizumab for MS during the post-
RiskMAP period. Although AERS is incapable of detecting the true frequency of an 
adverse event associated with a drug or assessing the actual causal relationship, these
reports of natalizumab-associated PML indicate that continued surveillance and
further epidemiologic study is necessary.
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OBJECTIVES: To evaluate the impact of the patient’s adherence to national guideline 
in the treatment costs. METHODS: A one-year (January 2007 to December 2007) 
retrospective database search was conducted to identify medication used, costs, patient 
adherence and provision. The source of data was the Ministry of Health public avail-
able database, called DATASUS. The study were conduct in four steps: 1) Determine 
the medicines codes in the public list; 2) Establish the relationships among drugs and
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patients usage; 3) Analyze adherence pattern at country level, based on medication 
consumption; and 4) Estimate the impact of adherence in the treatment costs. 
RESULTS: Medication for MS was responsible by 12.9% of high cost medication 
supplied by Public Sector in Brazil. During the period of analysis an average of 34.4% 
of patients adhere to treatment from 10 to 12 months. Patients treated were distributed
among therapeutics alternative as follow: 60.66% to interferon-1a (two brands), 
20.5% to interferon-1b and 18.85 to glatiramer acetate. It was possible to detect an
increase in drugs association. We found the following adherence per treatment: 36.9%
to glatiramer acetate, 33.67% to interferon-1a (two brands) and 32.3% to interferon-
1b. Due to these levels of adherence the annual costs per patient treated was USD
27,824 to glatiramer acetate, US$42,151 to interferon-1a (two brands) and US$34,038 
to interferon-1b. Total treatment costs was higher than USD92 millions per year
(R$2.5 / USD1.0), the distribution of costs begins to diverge from patients distribution 
due to combination therapy. CONCLUSIONS: National guidelines standardize care, 
but the analysis of treatment patterns points to low treatment adherence. Due to actual 
levels of adherence the costs per patient treated was three times higher than the 
expected. Actions taken to change these levels will have a considerable impact to 
reduce the cost per patient treated.
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OBJECTIVES: The objective of the study was to characterize variance in the utilization 
of immunosuppressant agents among kidney transplant patients across academic 
medical centers (AMC), and to illustrate potential differences in clinical and economic
outcome measures. METHODS: A retrospective database analysis, representing 
48 AMCs participating in the University HealthSystem Consortium’s (UHC) Clinical 
Resource Manager (CRM), was conducted on inpatients discharged between July
2007 and June 2008. Administrative data examined included total discharges for 
kidney transplants, source of renal allograft, cases with complications, immunosup-
pressant utilization, length of therapy (LOT), length of stay (LOS), days in intensive 
care unit (ICU), in-hospital mortality rate, estimated immunosuppressant cost, and 
estimated hospital costs. Descriptive statistics were used to evaluate data. RESULTS:
The mean LOT and number of institutions utilizing particular agents varied. Cyclo-
sporine was used in an average 16% of transplants. Tacrolimus and mycophenolate
mofetil had a mean utilization of 83% (4% to 100%) and 92% (39% to 100%) 
respectively. Sirolimus and azathioprine were administered in an average 12% (1% to
75%) and 2% (1% to 8%) respectively. Antithymocyte globulin, equine was dis-
pensed in an average 28% (1% to 91%) of cases. Antithymocyte globulin, rabbit was
used in an average 53% (1% to 100%) of cases. Basiliximab and daclizumab were 
utilized in an average 31% (1% to 96%) and 33% (1% to 89%). Thirty-three institu-
tions utilized three or more agents in greater than 50% of their kidney transplants. 
Agents that contributed most signiﬁ cantly to immunosuppressant cost were antithy-
mocyte globulin and basiliximab. The mean LOS index was 1.1 (0.6 to 1.7). The mean
days spent in the ICU was 2.8 (1.6 to 8.0) days. The mean in-hospital mortality rate 
was 0.47%. The estimated average immunosuppressant cost per case was $4249.
CONCLUSIONS: Considerable variation exists among institutional utilization of 
immunosuppressive agents, LOT, and associated medication costs per case.
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OBJECTIVES: Abnormalities in mineral metabolism (MM) are associated with 
increased morbidity and mortality in patients with chronic kidney disease (CKD). 
PhotoGraphTM software was designed to allow dialysis centres to track MM and
assess treatment efﬁ cacy. Recent studies in other patient populations have suggested 
that restricted access to drugs was associated with poorer patient outcomes in the 
Canadian health care setting. The aim of this study was to compare MM management 
among dialysis patients who live in provinces with open vs. restricted access to
expensive drugs. METHODS: A sample of 50 Canadian dialysis centres which used 
PhotoGraphTM were selected. Phosphorus (P), calcium (Ca), intact parathyroid
hormone (iPTH) and calcium-phosphate product (CaXP) were measured and com-
pared between provinces with open and restricted access. Data were analyzed by
phosphate binder type. RESULTS: MM targets were more likely to be reached by 
patients residing in provinces with formularies allowing more open access to non-
calcium based phosphate binders: P: 61.6% vs. 54.9%; Ca: 59% vs. 44.8%; iPTH:
31.1% vs. 27.3%; CaXP: 85.4% vs. 76.9%. Patients residing in provinces with more 
restrictive formularies were more likely to receive doses of calcium that exceed the
maximum recommended in treatment guidelines (i.e., 1.5 g/day) than those with 
more open listings (62% vs. 15%). In addition, patients residing in provinces with
restricted access to sevelamer were less likely to receive this drug (16.2% vs. 42%).
CONCLUSIONS: MM was better managed among patients in settings with more open 
access to non-calcium based phosphate binders. There is a reasonable expectation that 
this may translate to better outcomes and reduced mortality among hemodialysis 
patients.
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OBJECTIVES: Cardiovascular disease is the leading cause of death among patients
with chronic kidney disease (CKD). Vascular calciﬁ cation (VC) is a common feature 
of CKD that predicts mortality and may contribute to future outcomes. CKD treatment 
guidelines recommend that calcium-based phosphate binders (CBBs) be restricted to 
doses of 1.5 g/day elemental calcium, however a previous study showed that this dose 
was associated with VC in CKD. Similarly, the use of calcium (1.5 g/day) has been 
associated with poorer cardiovascular outcomes in other patient populations (e.g., 
postmenopausal women). The aim of this review was to compare the prevalence of 
VC among CKD patients treated with CBBs and sevelamer. METHODS: A literature 
search using Medline was conducted using the following terms: CBB, calcium carbon-
ate, calcium acetate, non-CBB, sevelamer, lanthanum, vascular calciﬁ cation, coronary
and aorta. Studies reporting mean changes from baseline (%) in VC scores in CBB 
and sevelamer groups were used for data extraction. RESULTS: Increased progression 
of coronary calciﬁ cation was observed in CBB groups as compared to sevelamer:
13.4% to 50.8% vs. 8.0% to 23.4% (n  6 studies). Sevelamer was associated with 
regression of aortic calciﬁ cation compared to CBBs: 71.3% to 13.4% vs. 5.7% to 
135% (n  3 studies). Average doses of calcium ranged from 1.39 to 2.3 g/day. 
CONCLUSIONS: Although the doses of elemental calcium used in these studies
approached those recommended by treatment guidelines, CBBs were associated with
increased progression of VC. CBBs are associated with increased VC, a predictor for 
mortality, even when calcium doses concur with current standards of practice. More
research on the impact of CBBs on VC and future outcomes is required.
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OBJECTIVES: Two-thirds of patients with Chronic Kidney Disease (CKD) will die of 
cardiovascular disease (CVD). In addition, 30 year old dialysis patients have a 500-
fold increased mortality risk vs. an age-matched general population. Coronary artery 
calciﬁ cation (CAC) is a major risk factor for CVD in CKD patients. Increased serum 
calcium accelerates this process, which suggests that calcium-based phosphate binders
(CBBs) may accelerate CAC and increase mortality. The aim of this systematic review
was to determine the effect of CBBs vs. non-CBBs on all-cause mortality and CAC
among patients with CKD. METHODS: We conducted a detailed search of several
electronic databases (e.g., MEDLINE, EMBASE, CINHAL) using the following terms: 
kidney disease, phosphate binders, calcium dialysis, phosphate levels, CV events and 
mortality. Standard Cochrane methods for study selection and data abstraction were
followed. We included nine studies which compared CBBs to non-CBBs. RESULTS:
Fifty-seven articles were retrieved for detailed evaluation. Sevelamer was the only
non-CBB noted in the nine trials which met the inclusion criteria. Sevelamer was 
associated with a trend towards reduction in all-cause mortality (RR 0.81; 95% CI 
0.65–1.02), p  0.07 vs. CBBs. Overall difference in change of CAC scores among 
those taking sevelamer vs. CBBs was 76.35 (95% CI 158.25 – 5.55), p  0.07. 
CONCLUSIONS: Compared to CBBs, sevelamer is associated with a non-signiﬁ cant 
trend toward reduced all-cause mortality. This is concordant with the trend toward a 
modest reduction in CAC progression with sevelamer. Since CBBs are used frequently 
in CKD patients, this systematic review highlights the need to further evaluate the 
safety of CBBs in this high-risk population.
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OBJECTIVES: This study aimed to compare the life expectancy, expected years of life 
lost (EYLL) and survival between patients under hemodialysis (HD) and peritoneal
dialysis (PD). METHODS: Adult patients who underwent maintenance dialysis at
National Taiwan University Hospital from 1995 to 2006 were followed-up until the 
